Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMV Vaccine With or Without Checkpoint Inhibitors in TNBC
NCT06324240Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tumor membrane vesicle vaccine in triple-negative breast cancer (TNBC) (3 arms), sponsored by Emory University. Primary endpoints: Incidence of adverse events at 2 years and Dose limiting toxicity at 5 weeks. Started Dec 2025; status: recruiting.
02
Drugs
tumor membrane vesicle vaccine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06324240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324240.